# Delta-Tocotrienol

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/delta-tocotrienol
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 4 / 10
**Category:** Vitamin
**Also Known As:** (2R,4'R,8'R)-δ-tocotrienol, δ-T3, Delta-T3, δ-tocotrienol, D-delta-tocotrienol, Palm vitamin E delta, Unsaturated vitamin E delta

## Overview

Delta-tocotrienol is the most biologically active isoform of vitamin E tocotrienols, characterized by its unsaturated phytyl tail that enables superior membrane mobility compared to tocopherols. It exerts its primary effects through suppression of the mevalonate pathway, [NF-κB](/ingredients/condition/inflammation) signaling inhibition, and induction of apoptosis in cancer cells via upregulation of pro-apoptotic proteins.

## Health Benefits

• Reduces chemotherapy toxicity: Phase II RCT showed fewer oxaliplatin dose reductions (47% vs 71%, p=0.047) in colorectal cancer patients (PMID: 37646150)
• Improves [liver function](/ingredients/condition/detox) in NAFLD: RCT demonstrated significant improvements in ALT/AST, steatosis scores, and [insulin resistance](/ingredients/condition/weight-management) (p<0.001) over 24 weeks (PMID: 32951743)
• Stabilizes advanced cancer: 70% disease stabilization rate in bevacizumab-refractory ovarian cancer with median PFS of 6.9 months (PMID: 30639384)
• Enhances glycemic control: RCT in pre-diabetic patients showed improved HbA1c and fasting glucose levels (PMID: 35099428)
• Reduces [inflammation](/ingredients/condition/inflammation) and [oxidative stress](/ingredients/condition/antioxidant): Pilot RCT found significant reductions in hs-CRP and MDA markers (p<0.001) in NAFLD patients (PMC6284694)

## Mechanism of Action

Delta-tocotrienol inhibits HMG-CoA reductase in the mevalonate pathway, reducing isoprenylation of Ras and Rho GTPases that drive cancer cell proliferation. It suppresses [NF-κB](/ingredients/condition/inflammation) activation by preventing IκB kinase phosphorylation, thereby downregulating pro-survival genes including Bcl-2, cyclin D1, and VEGF. Additionally, it activates PPAR-γ receptors and reduces oxidative stress by scavenging [reactive oxygen species](/ingredients/condition/antioxidant), contributing to its [hepatoprotective](/ingredients/condition/detox) and insulin-sensitizing effects observed in NAFLD models.

## Clinical Summary

A Phase II randomized controlled trial (PMID: 37646150) in colorectal cancer patients demonstrated that delta-tocotrienol supplementation significantly reduced oxaliplatin dose reductions compared to placebo (47% vs 71%, p=0.047), suggesting meaningful chemotherapy-protective activity. A separate RCT in NAFLD patients showed statistically significant reductions in ALT, AST, hepatic steatosis scores, and [insulin resistance](/ingredients/condition/weight-management) markers (p<0.001), indicating clinically relevant [hepatoprotective](/ingredients/condition/detox) effects. Evidence is currently limited to Phase I and Phase II trials with relatively small sample sizes, and large-scale Phase III confirmatory trials are not yet available. The existing data are promising but insufficient to establish definitive clinical guidelines without further replication in larger cohorts.

## Nutritional Profile

Delta-tocotrienol is one of four tocotrienol isomers (alpha, beta, gamma, delta) belonging to the vitamin E family. It is a fat-soluble secosteroid characterized by an unsaturated farnesyl (isoprenoid) side chain with three double bonds at positions 3', 7', and 11', distinguishing it from tocopherols which have a saturated phytyl side chain. Molecular formula: C27H40O2; molecular weight: 396.6 g/mol. It is not a macronutrient source and contains no fiber, protein, or carbohydrates. Bioactive compound: delta-tocotrienol itself is the primary bioactive, with concentrations in supplement form typically ranging from 100–300 mg per capsule (clinical trials have used doses of 200–1600 mg/day). Natural dietary sources include annatto seeds (which contain ~90% delta-tocotrienol and ~10% gamma-tocotrienol, with virtually no tocopherols, at concentrations of approximately 150–200 mg tocotrienols per gram of annatto extract), rice bran oil (~10–15 mg total tocotrienols per 100 g, with delta-tocotrienol comprising a minor fraction), palm oil (~30–80 mg total tocotrienols per 100 g, delta-tocotrienol comprising ~5–10% of total tocotrienols), and barley (~1–5 mg/100 g total tocotrienols). Bioavailability notes: As a fat-soluble compound, absorption is significantly enhanced when taken with a fat-containing meal (up to 2–3 fold increase in plasma levels). Delta-tocotrienol has a shorter plasma half-life (~3–4 hours) compared to alpha-tocopherol (~20–57 hours) due to rapid [metabolism](/ingredients/condition/weight-management) via omega-hydroxylation and beta-oxidation of the side chain, yielding carboxychromanol metabolites excreted in urine and feces. Oral bioavailability is estimated at 10–30% and is subject to first-pass hepatic metabolism. Self-emulsifying drug delivery systems (SEDDS) and nanoformulations have been shown to improve bioavailability by 2–5 fold. Importantly, concurrent supplementation with alpha-tocopherol can competitively inhibit delta-tocotrienol absorption and tissue uptake via the alpha-tocopherol transfer protein (α-TTP), which preferentially binds alpha-tocopherol. Delta-tocotrienol exhibits superior [antioxidant activity](/ingredients/condition/antioxidant) compared to alpha-tocopherol in membrane models due to its unsaturated side chain allowing more uniform distribution in lipid bilayers and more efficient radical scavenging. Key bioactive mechanisms include [NF-κB](/ingredients/condition/inflammation) pathway inhibition (IC50 ~1–5 µM in cell models), HMGR (3-hydroxy-3-methylglutaryl-CoA reductase) downregulation via post-transcriptional suppression, induction of apoptosis in cancer cells via caspase-8 and caspase-3 activation, and modulation of VEGF-mediated angiogenesis.

## Dosage & Preparation

Clinical trials used 300-900 mg/day in divided doses, typically as softgel capsules with ≥90% purity. Cancer trials: 900 mg/day (300 mg three times daily). NAFLD: 600 mg/day (300 mg twice daily) for 12-24 weeks. Absorption enhanced 2-3x when taken with food/fats. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Delta-tocotrienol is generally well-tolerated at studied doses (200–400 mg/day), with mild gastrointestinal symptoms such as nausea and bloating reported in a minority of participants. Due to its inhibition of HMG-CoA reductase, concurrent use with statins such as atorvastatin may produce additive lipid-lowering effects, warranting monitoring for myopathy risk. Its antiplatelet properties mean caution is advised when combined with anticoagulants such as warfarin or antiplatelet drugs like clopidogrel, as bleeding risk may be potentiated. Safety data in pregnancy and lactation are insufficient; use is not recommended during pregnancy without physician supervision.

## Scientific Research

Multiple phase II randomized controlled trials support delta-tocotrienol's clinical benefits, though larger phase III trials are lacking. Key studies include RCTs in metastatic colorectal cancer (n=70, PMID: 37646150), breast cancer (n=80, PMID: 37225860), and NAFLD (24 weeks, PMID: 32951743), with doses ranging from 300-900 mg daily showing good tolerability up to 2 years.

## Historical & Cultural Context

No established traditional use exists for isolated delta-tocotrienol as it is a modern isolate identified in palm oil research since the 1980s. While palm oil has been used in Southeast Asian traditional medicine for wound healing and nutrition, specific targeting of delta-tocotrienol effects like cancer or liver disease is a contemporary development.

## Synergistic Combinations

Alpha-tocopherol, Omega-3 fatty acids, Milk thistle, Berberine, Curcumin

## Frequently Asked Questions

### What is the difference between delta-tocotrienol and vitamin E?

Conventional vitamin E supplements typically contain alpha-tocopherol, which has a saturated phytyl tail limiting its membrane mobility. Delta-tocotrienol belongs to the tocotrienol subfamily with an unsaturated tail, granting it 40–60 times greater antioxidant potency in lipid membranes and unique anti-cancer and cholesterol-lowering activities that alpha-tocopherol does not share. These structural differences make delta-tocotrienol pharmacologically distinct from standard vitamin E despite belonging to the same family.

### What is the effective dose of delta-tocotrienol in clinical trials?

Clinical trials have most commonly used doses ranging from 200 mg to 400 mg per day of delta-tocotrienol, typically administered orally in divided doses with meals to enhance absorption given its fat-soluble nature. The Phase II colorectal cancer trial used 300 mg/day alongside standard chemotherapy, while NAFLD studies have used doses in the 200–400 mg range over 12–24 weeks. Optimal dosing has not been definitively established, and formulation quality significantly impacts bioavailability.

### Can delta-tocotrienol help with fatty liver disease (NAFLD)?

An RCT in NAFLD patients demonstrated that delta-tocotrienol supplementation produced significant reductions in liver enzymes ALT and AST, ultrasound-measured hepatic steatosis scores, and markers of insulin resistance, all with p-values below 0.001. These effects are attributed to PPAR-γ activation, NF-κB-mediated anti-inflammatory action, and reduction of lipid peroxidation in hepatocytes. While results are encouraging, larger multicenter trials are needed before it can be recommended as a standard therapeutic intervention for NAFLD.

### Does delta-tocotrienol interact with chemotherapy drugs?

A Phase II RCT (PMID: 37646150) found that delta-tocotrienol reduced the frequency of oxaliplatin dose reductions due to neurotoxicity (47% vs 71%, p=0.047) in colorectal cancer patients, suggesting a protective rather than antagonistic interaction. Its cytoprotective effects appear to be selective, targeting normal cells via antioxidant pathways while maintaining or potentially enhancing cancer cell apoptosis through NF-κB suppression. However, oncologists should be consulted before co-administration, as interactions with other chemotherapy regimens have not been fully characterized.

### Does delta-tocotrienol lower cholesterol?

Delta-tocotrienol inhibits HMG-CoA reductase, the same enzyme targeted by statin drugs, thereby reducing hepatic cholesterol synthesis. Preclinical studies and early human data suggest it can lower total cholesterol and LDL-cholesterol, though the magnitude of effect in human RCTs is modest compared to pharmaceutical statins. Because of this shared mechanism, combining delta-tocotrienol with prescribed statins may produce additive effects and should be discussed with a healthcare provider to avoid over-suppression of the mevalonate pathway.

### What food sources naturally contain delta-tocotrienol?

Delta-tocotrienol is found primarily in plant oils and seeds, with palm oil, rice bran oil, and annatto being the richest natural sources. Nuts, seeds, and whole grains contain smaller amounts, but obtaining clinically effective doses (typically 300–600 mg) from diet alone is challenging. Supplementation is generally recommended for therapeutic benefits demonstrated in clinical research.

### Is delta-tocotrienol safe during pregnancy and breastfeeding?

Limited clinical data exists on delta-tocotrienol safety during pregnancy and breastfeeding, so it is generally not recommended during these periods without medical supervision. Pregnant and nursing women should consult their healthcare provider before supplementing, as vitamin E forms can affect pregnancy outcomes at high doses. Standard prenatal vitamins provide safer, established levels of vitamin E nutrition.

### How strong is the clinical evidence for delta-tocotrienol in cancer patients?

Phase II clinical trials provide encouraging evidence for delta-tocotrienol in cancer support, including a randomized controlled trial showing reduced chemotherapy toxicity (fewer oxaliplatin dose reductions in colorectal cancer) and disease stabilization rates around 70% in advanced cancer patients. However, these are relatively small, early-stage studies, and larger Phase III trials are needed to confirm efficacy and establish it as standard adjunctive therapy. Current evidence supports its investigation as a potential supportive agent but not as a primary cancer treatment.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*